PFA Pension Forsikringsaktieselskab Buys Shares of 35,405 Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• PFA Pension bought a new stake of 35,405 shares of Alnylam in Q4, valued at about $14.07 million, while institutional investors collectively own roughly 92.97% of the stock.
• Q1 results beat expectations: Alnylam reported EPS of $1.99 vs. $0.90 expected and revenue of $1.17B (up ~96% YoY), driven by an ~187% surge in Amvuttra sales.
• Analyst sentiment is broadly positive with a consensus rating of "Moderate Buy" and an average price target of about $471.96, as most analysts maintain Buy or Outperform views.

PFA Pension Forsikringsaktieselskab bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 35,405 shares of the biopharmaceutical company's stock, valued at approximately $14,065,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ALNY. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $25,000. Salomon & Ludwin LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $32,000. Finally, ORG Partners LLC raised its holdings in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 33 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group reaffirmed a "hold" rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Chardan Capital reaffirmed a "buy" rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Truist Financial cut their price target on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating on the stock in a report on Monday, April 13th. Barclays assumed coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an "overweight" rating and a $527.00 price target on the stock. Finally, Royal Bank Of Canada cut their price target on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an "outperform" rating on the stock in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $471.96.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the sale, the executive vice president owned 64,273 shares of the company's stock, valued at $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Melissa Mclaughlin sold 2,286 shares of the business's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,656 shares of company stock valued at $12,370,696 over the last 90 days. Corporate insiders own 0.86% of the company's stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $296.11 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $245.96 and a 12 month high of $495.55. The stock has a market cap of $39.51 billion, a price-to-earnings ratio of 80.90 and a beta of 0.31. The stock's 50 day moving average price is $320.11 and its 200 day moving average price is $376.18. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.90 by $1.09. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same quarter in the previous year, the company earned ($0.44) earnings per share. The firm's quarterly revenue was up 96.4% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.